This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Introduction Catheter ablation is an effective and safe strategy for treating atrialfibrillation patients. Nevertheless, studies on the long-term outcomes of catheter ablation in patients with dilated cardiomyopathy are limited. years following catheter ablation.
When atrialfibrillation (AF) begins, it can start with a single focus, degenerating to multiple wavelets, and it spreads throughout the entire surface area of both atria. A fibrillatory wave that occurs at a rate of more than 600 beats per minute can cause fatigue in the long run, leading to atrial dilation.
Catheter ablation of atrialfibrillation in infiltrative cardiomyopathies ABSTRACT Atrial and ventricular arrhythmias are common in patients with Infiltrative heart diseases. AF is the most common arrhythmia identified in patients with amyloidosis due to cellular infiltration and atrial dilation.
American College of Cardiology (ACC) and American Heart Association (AHA) Issue New Hypertrophic Cardiomyopathy (HCM) Management Guidelines 2. Late-breaking Clinical Trial Results from FARADISE, admIRE Study and Advent Trial at Heart Rhythm 2024 Highlight Pulsed Field Ablation Developments for AtrialFibrillation Treatment 8.
What is the impact of atrialfibrillation (AF) catheter ablation in patients with hypertrophic cardiomyopathy (HCM) on reduction in AF burden and symptoms?
Atrialfibrillation (AF) is common in patients with hypertrophic cardiomyopathy (HCM) and can be challenging to manage. Atrioventricular nodal (AVN) ablation may be an effective management strategy for AF in these patients.
In patients with hypertrophic cardiomyopathy (HCM), atrialfibrillation (AF) poses significant clinical challenges because of its adverse impact on hemodynamics. AF, especially when accompanied by rapid ventricular responses, compromises atrial contraction and in turn increases diastolic filling of the left ventricle.
Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) is often accompanied by atrialfibrillation (AF), atrial flutter (AFL), and atrial tachycardia (AT), which are difficult to control because beta-blockers and antiarrhythmic drugs can worsen heart failure (HF).
Atrialfibrillation (AF), a common cardiac arrhythmia, often results in significant atrial remodeling, including atrialcardiomyopathy and dilatation. Notably, aFMR is linked to a higher recurrence rate of AF after catheter ablation.
ABSTRACT Atrialfibrillation (AF) is the most common cause of arrhythmia-induced cardiomyopathy. Effective management strategies include medical therapy for rate and rhythm control, catheter ablation (CA), and goal-directed medical therapy.
Abstract Introduction In hypertrophic cardiomyopathy (HCM), atrialfibrillation (AF) has historically been regarded to have a deleterious impact on clinical course, strongly associated with progressive heart failure (HF) symptoms. Results Among the 218 patients, 50 (23%) had a history of AF and comprise the primary study cohort.
Cardiac amyloidosis (CA) involves the abnormal accumulation of misfolded proteins in the heart muscle, leading to restrictive cardiomyopathy.1 Atrial arrhythmias (AA), particularly atrialfibrillation (AF), are prevalent in CA and may impact long-term cardiovascular outcomes, prompting an investigation into early rhythm management strategies.2
Atrialcardiomyopathy is known as an underlying pathophysiological factor in the majority of AF patients. Left atrial low-voltage areas (LVAs) are reported to coincide with fibrosis, and to likely represent atrialcardiomyopathy.
Atrioventricular nodal (AVN) ablation with permanent pacemaker implantation – ‘pace and ablate’ – may be considered for patients with symptomatic atrialfibrillation (AF) for whom rhythm control has been unsuccessful. Conduction-system pacing mitigates PICM, so we expect a greater uptake of AVN ablation going forward.
While studies have linked this genetic mutation to severe cardiac hypertrophy, a connection to persistent atrialfibrillation (AF) is unestablished. After three unsuccessful cardioversions and refractory episodes despite Dronedarone therapy, he was scheduled for an ablation. He was loaded with amiodarone.
She was found to have atrialfibrillation and flutter with RVR. She remained in flutter despite diuresis, rate control with metoprolol and digoxin, cardioversion, and ablation. Cardiomyopathy and arrhythmia have been described in a small number of cases.
BACKGROUND:The cause of hypertrophic cardiomyopathy (HCM) in the young is highly varied. Six (21%) patients had clinical atrialfibrillation (1 with shortest preexcited RR interval <250 ms). Ablation was acutely successful in 13 of 14 patients with recurrence in 3.
Atrialcardiomyopathy represents structural and electrophysiologic abnormalities associated with atrialfibrillation (AF). Fibrosis, visualized with late gadolinium enhancement on cardiac magnetic resonance imaging (MRI), is associated with low voltage on electroanatomic mapping1, and ablation outcomes 2.
Background:Obstructive sleep apnoea (OSA) is highly prevalent in patients with obstructive hypertrophic cardiomyopathy (oHCM), and the severity of OSA appears to worsen following septal myoectomy. vs. 27.77 ± 3.26, p<0.001), a higher proportion of atrialfibrillation, hypertension, and history of smoking.
Hypertrophic cardiomyopathy is a genetic disorder with a guarded prognosis which occurs in about 1:500 individuals. The most common symptom of hypertrophic cardiomyopathy is dyspnoea which occurs in 90% of cases and is due to elevated left ventricular diastolic pressures as a consequence of the diastolic dysfunction.
24 will focus on the following three current guideline updates: American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines 2023 AtrialFibrillation Guideline - Pharmacology II: Strokes vs. Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? The Guidelines Sessions at ACC.24 12:15 p.m.
Within the last six months, separate AI-ECG algorithms for detecting Low Ejection Fraction (Anumana), Hypertrophic cardiomyopathy (Viz.ai), and Occlusion Myocardial infarction (Powerful Medical) have all been granted regulatory clearance (the latter under the EU MDR) and are in the early stages of deployment.
It is dangerous in WPW with atrialfibrillation. In AtrialFibrillation, the tachycardia will always be irregularly irregular. In Atrial fib with WPW, there will be polymorphic QRS complexes (in this case, all QRS complexes are identical). VT is not harmed by adenosine, When is adenosine dangerous?
A patient in the ICU with significant underlying cardiac disease [HFrEF 30%, non-ischemic cardiomyopathy, LBBB s/p CRT-D (biventricular pacer), AVNRT s/p ablation a few yrs ago, hx sinus tachycardia while on max tolerated BB therapy] went into a regular wide-complex tachycardia after intubation for severe COPD exacerbation.
They had a history of non-ischemic cardiomyopathy (EF 30%), as well as PCI with one stent. Detail of Flutter waves The rate of the flutter waves matches the rate of the WCT (about 200/m), proving that the presenting WCT had been 1:1 atrial flutter. The subsequent EP study could not induce VT, only atrialfibrillation.
She also has a hx of paroxysmal atrialfibrillation and is on oral anticoagulant treatment. After atrial rhythm/SR was restored the patient slowly improved. Medical treatment for heart failure was optimized and after a few days the patient was discharged with referral to VT ablation procedure.
Institutional Coronary Artery Bypass Case Volumes and Outcomes European Journal of Heart Failure October 2023 Makoto Mori Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation The Annals of Thoracic Surgery August 2023 Carlos Diaz-Castrillion Volume-Failure to Rescue Relationship in Acute Type A Aortic Dissections: An Analysis of The Society (..)
Institutional Coronary Artery Bypass Case Volumes and Outcomes European Journal of Heart Failure October 2023 Makoto Mori 1 Robotic Mitral Valve Repair for Degenerative Mitral Regurgitation The Annals of Thoracic Surgery August 2023 Carlos Diaz-Castrillion 2 Volume-Failure to Rescue Relationship in Acute Type A Aortic Dissections: An Analysis of The (..)
Introduction Atrialfibrillation (AF)-induced cardiomyopathy (AIC) is retrospectively defined after normalisation of left ventricular ejection fraction (LVEF) in sinus rhythm. Detailed assessment of cardiac function after successful catheter ablation will reveal this. It is unclear why some patients develop AIC.
Atrail electroanatomic voltage mapping (Atrial-EAVM) and late gadolinium enhancement imaging (Atrial-LGE) quantify the functional and anatomic extent of atrial fibrosis, a central component of atrialcardiomyopathy. Atrial-EAVM and Atrial-LGE correlated with greatest agreement at high-fibrosis burdens.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content